Medical News

RSS

Eisai's LUSEDRA Injection now available for MAC sedation

Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

16 Nov 2009

Update from Novo Nordisk regarding its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

16 Nov 2009

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug market -- driven by the launches of several novel therapies -- will increase from $6 billion in 2008 to $9.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Nov 2009

Bravo Health to open its first Advanced Care Center in Philadelphia

Bravo Health today announced that the first Bravo Health Advanced Care Center (the Center) will open in Philadelphia in January 2010. The Center, an innovative, state-of-the-art outpatient physician practice designed to meet the health care needs of Bravo Health members, will be located in a new building being constructed at 1010 W. Lehigh Avenue in North Philadelphia.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Benenden selects Databarracks for online backup service

Benenden Hospital was founded in 1907 and became the centre for hospital treatment for members of Trade Unions and Friendly Societies and subsequently large numbers of public sector employees who joined what is now the Benenden Healthcare Society. The Society has over 900,000 member and nominee subscribers.

16 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Neogen's Board of Directors approves a 3-for-2 stock split

Neogen Corporation today announced that its Board of Directors has approved a 3-for-2 stock split. With the split, shareholders of record on Nov. 30, 2009, will receive one additional share of stock for each two shares held.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Researchers, decision makers, and people with HIV to attend Ontario HIV Treatment Network's conference

The 11th annual research conference of the Ontario HIV Treatment Network will examine the factors that increase risk for individuals and communities most affected by HIV, as well as interventions that may improve the lives of people living with HIV and prevent the spread of the virus.

16 Nov 2009

Eyes turn to Lieberman, Reid, Snowe as most crucial health reform players

Bloomberg reports that Sen. Joe Lieberman's "independence (is hindering) Democrats' health-care end game."

16 Nov 2009

Brookstone Pharmaceuticals changes its name to Acella Pharmaceuticals

Brookstone Pharmaceuticals, an emerging specialty pharmaceutical company, announced today its decision to change the name of the company to Acella Pharmaceuticals, LLC. This decision has been made to create a company image and brand that more accurately mirrors our commitment to "Accelerating the Health Care Solution" by bringing quality affordable products to customers and patients. Mark Pugh, CEO states, "As we have grown over the last few years, we have evolved into a more integrated pharmaceutical company.

16 Nov 2009

Third-quarter fiscal 2009 results announced by GeneLink

GeneLink, Inc., a leading consumer genomics biotech company, today reported financial results for the fiscal 2009 three-month period ended September 30, 2009.

16 Nov 2009

New mobile yoga class app for iPhone and iPod Touch iPractice 2.0 released

Yoga Journal magazine today announced the release of iPractice 2.0, a new mobile yoga class app for iPhone and iPod Touch. Yoga Journal iPractice features 15 complete yoga classes designed specifically to take advantage of the iPhone's capabilities and interface.

16 Nov 2009

Electronic health records not yet making impact, patients turn to web for advice

As the United States launches "an ambitious program, backed by $19 billion in government incentives, to accelerate the adoption of computerized patient records in doctors' offices and hospitals," a new study of 3,000 hospitals "has found little difference in the cost and quality of care," The New York Times reports.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

4SC raises funds for further development of its current product pipeline

4SC AG, a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009.

16 Nov 2009

Health lobbying ranges from below the radar to high profile

A Charlotte, N.C., law firm is operating a secretive group called Americans for Quality and Affordable Healthcare to attempt to shape lawmakers' and the public's opinions on health reform, the Associated Press reports.

16 Nov 2009

Drug makers hike prices, lobby hard as reform efforts progress

Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect." The increases "will add more than $10 billion to the nation's drug bill, which is on track to exceed $300 billion this year."

16 Nov 2009

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

16 Nov 2009